Physician profile
Meetkumar T Sheth
NPI 1164680500
$15,247.79
in general payments reported to CMS, 2019-2025
49 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $1,735 · 2021: $2,322 · 2022: $2,467 · 2023: $2,843 · 2024: $2,194 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,895.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,369.48 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,746.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,266.49 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,197.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,058.61 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $670.04 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $669.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $659.72 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $658.65 | 2019-2023 | Livalo, Seglentis |
| Amgen INC. | $622.90 | 2021-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $551.72 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $433.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $313.60 | 2019-2024 | Verquvo |
| Dexcom, INC. | $303.90 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $275.78 | 2019-2025 | Trintellix |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meetkumar Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.